clazakizumab | Clazakizumab

Keyword	CPC	PCC	Volume	Score	Length of keyword
clazakizumab	0.48	0.3	2438	22	12

Keyword	CPC	PCC	Volume	Score
clazakizumab	1.05	0.7	1027	56
clazakizumab fda approval	1.62	0.7	8204	79
clazakizumab clinical trials	0.5	0.3	6386	10
clazakizumab binding affinity	0.4	0.2	9376	63
clazakizumab fda	1.07	0.6	1233	96
clazakizumab csl	0.9	0.5	995	90
clazakizumab amr	0.58	0.5	6934	95
clazakizumab covid	0.39	0.6	174	61
clazakizumab cancer	0.1	0.4	2864	32
clazakizumab asthma	0.28	1	9375	69

Search Results related to clazakizumab on Search Engine

Clazakizumab - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Clazakizumab

WEBClazakizumab (formerly ALD518 and BMS-945429 ), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6. [1] . Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals.

DA: 42 PA: 17 MOZ Rank: 94

Translating IL-6 biology into effective treatments - Nature
nature.com

https://www.nature.com/articles/s41584-020-0419-z

WEBApr 23, 2020 · The therapeutic benefit of this antibody to IL-6R led to the development of several antibodies to IL-6 (sirukumab, olokizumab and clazakizumab).

DA: 91 PA: 62 MOZ Rank: 87

Clazakizumab for the treatment of chronic active antibody …
biomedcentral.com

https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-022-06897-3

WEBDec 22, 2022 · Clazakizumab is a high-affinity, humanized monoclonal antibody that binds interleukin-6 and decreases donor-specific antibody (DSA) production and inflammation.

DA: 31 PA: 50 MOZ Rank: 98

Clazakizumab - an overview | ScienceDirect Topics
sciencedirect.com

https://www.sciencedirect.com/topics/medicine-and-dentistry/clazakizumab

WEBClazakizumab (humanized anti-IL6) has shown promising results for the treatment of RA as well as psoriatic arthritis; by virtue of engineered aglycosylation, clazakizumab has a longer half-life than other monoclonal reagents targeting IL-6 or IL-6R, thereby requiring less frequent dosing.

DA: 16 PA: 53 MOZ Rank: 67

A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920172/

WEBDec 18, 2020 · Clazakizumab is a humanized monoclonal IgG1 antibody with high affinity for IL-6 and a long t 1/2 of approximately 30 days. This antibody has been systematically evaluated in rheumatoid and psoriatic arthritis, 10 , …

DA: 29 PA: 44 MOZ Rank: 69

Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039906/

WEBFeb 9, 2022 · Results. LTE patients received clazakizumab for >2.5 years. Mean eGFRs showed significant declines from −24 months to study initiation (0 months) (52.8 ± 14.6 to 38.11 ± 12.23 ml/min per 1.73 m 2, P = 0.03).

DA: 52 PA: 18 MOZ Rank: 72

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab
nih.gov

https://pubmed.ncbi.nlm.nih.gov/35583232/

WEBSep 1, 2022 · Clazakizumab significantly improved 28-day ventilator-free survival, 28- and 60-day overall survival, as well as clinical outcomes in hospitalized patients with COVID-19 and hyperinflammation. A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation

DA: 7 PA: 19 MOZ Rank: 98

A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab ... - PubMed
nih.gov

https://pubmed.ncbi.nlm.nih.gov/33443079/

WEBMethods: We performed a phase 2 randomized pilot trial to evaluate the safety (primary endpoint) and efficacy (secondary endpoint analysis) of the anti-IL-6 antibody clazakizumab in late ABMR. The trial included 20 kidney transplant recipients with donor-specific, antibody-positive ABMR ≥365 days post-transplantation.

DA: 5 PA: 80 MOZ Rank: 35

A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab
lww.com

https://journals.lww.com/ccmjournal/Fulltext/2022/09000/A_Randomized_Double_Blinded_Placebo_Controlled.7.aspx

WEBClazakizumab is a genetically engineered humanized monoclonal antibody with high affinity for human interleukin-6 (IL-6) that has been studied in disease states associated with hyperinflammation, including rheumatologic conditions ( 21, 22 ).

DA: 38 PA: 50 MOZ Rank: 55

A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizum ... - LWW
lww.com

https://journals.lww.com/jasn/Fulltext/2021/03000/A_Randomized_Clinical_Trial_of_Anti_IL_6_Antibody.21.aspx

WEBClazakizumab is a humanized monoclonal IgG1 antibody with high affinity for IL-6 and a long t1/2 of approximately 30 days. This antibody has been systematically evaluated in rheumatoid and psoriatic arthritis, 10, 15 but has not yet been approved for clinical use.

DA: 20 PA: 11 MOZ Rank: 89